-
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
-
ChemBase ID:
183
-
Molecular Formular:
C19H27N5
-
Molecular Mass:
325.45118
-
Monoisotopic Mass:
325.22664589
-
SMILES and InChIs
SMILES:
N1(CCN(CC1)c1c(cccc1)C)CCc1n2CCCCc2nn1
Canonical SMILES:
Cc1ccccc1N1CCN(CC1)CCc1nnc2n1CCCC2
InChI:
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
InChIKey:
RFWZESUMWJKKRN-UHFFFAOYSA-N
-
Cite this record
CBID:183 http://www.chembase.cn/molecule-183.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
H Acceptors
|
4
|
H Donor
|
0
|
LogD (pH = 5.5)
|
0.26387095
|
LogD (pH = 7.4)
|
1.9607973
|
Log P
|
2.4158738
|
Molar Refractivity
|
100.2216 cm3
|
Polarizability
|
37.01138 Å3
|
Polar Surface Area
|
37.19 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
Log P
|
2.78
|
LOG S
|
-2.64
|
Solubility (Water)
|
7.51e-01 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Solubility
|
Soluble
|
Show
data source
|
|
Hydrophobicity(logP)
|
2.3
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB00298
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia] |
Indication |
Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations. |
Pharmacology |
Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises. |
Toxicity |
Oral LD50 is 1189-2100 mg/kg in mice, rats and rabbits. |
Affected Organisms |
• |
Humans and other mammals |
|
Absorption |
Systemic absorption is negligible. |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent